Arginine

Arginine , Arginine, L-arginine

Arginine is a basic ##protein##, which is the main nitrogen carrier in the blood. The human body uses arginine to synthesize nitric oxide, which helps blood vessels relax and expand. This is important for regulating blood flow. Arginine can be used to treat a variety of health problems, but overconsumption can cause bone and skin disease.

Nutraceutic

  • Origin Plant Based, Animal Product, Synthetic
  • Source Milk, Eggs, Meat, Fish, Wheat Germs, Soybean, Beans, Chickpea, Peanuts, Walnuts, Hazelnut, Oatmeal, Spirulina Algae, pumpkin seeds, sunflower seeds
  • Type Amino Acid

Energy and Mood

Energy and mood are associated with several external and internal factors. Hormone release, brain chemical balance, nutrient metabolism, and several other elements alter the way the body and mind respond to daily activities. The compounds that benefit energy and mood are the ones that help in the balance of all these factors.
  • Anxiety

    Anxiety is the body's natural response to stress. It's a feeling of fear or apprehension about what's to come. It can be triggered by a specific situation and not last long - which is very common and ok - or it can be a generalized disorder (which is considered a illness) that can bring harm to everyday life and also cause other conditions like depression.
  • Age Range Adults (20-59)
  • Toxicity May be toxic in high doses
  • Side effects Nausea, Diarrhea, Gastrintestinal Disturbs
  • Warnings Diabetes Medication, Pregnancy, Hepatic Diseases, Cardiovascular Diseases

Why be Careful

High arginine dosage is related to health risks, because it may cause an overproduction of nitric oxide and consequent vasodilation and hypotension, as well as cell destructive potential. Excessive supplementation may increase blood sugar and potassium levels.

References

  1. a b Figueroa A, et al. Watermelon extract supplementation reduces ankle blood pressure and carotid augmentation index in obese adults with prehypertension or hypertensionAm J Hypertens. (2012)
  2. a b Corpas E, et al. Oral arginine-lysine does not increase growth hormone or insulin-like growth factor-I in old menJ Gerontol. (1993)
  3. a b Buford BN, Koch AJ. Glycine-arginine-alpha-ketoisocaproic acid improves performance of repeated cycling sprintsMed Sci Sports Exerc. (2004)
  4. a b Stevens BR, et al. High-intensity dynamic human muscle performance enhanced by a metabolic interventionMed Sci Sports Exerc. (2000)
  5. ^ Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyondBiochem J. (1998)
  6. ^ Arginine metabolism in mammals.
  7. ^ Malinauskas BM, et al. Supplements of interest for sport-related injury and sources of supplement information among college athletesAdv Med Sci. (2007)
  8. ^ Tharakan JF, et al. Adaptation to a long term (4 weeks) arginine- and precursor (glutamate, proline and aspartate)-free dietClin Nutr. (2008)
  9. a b c de Jonge WJ, et al. Overexpression of arginase I in enterocytes of transgenic mice elicits a selective arginine deficiency and affects skin, muscle, and lymphoid developmentAm J Clin Nutr. (2002)
  10. ^ de Jonge WJ, et al. Arginine deficiency affects early B cell maturation and lymphoid organ development in transgenic miceJ Clin Invest. (2002)
  11. ^ de Jonge WJ, et al. Overexpression of arginase alters circulating and tissue amino acids and guanidino compounds and affects neuromotor behavior in miceJ Nutr. (2001)
  12. ^ Kwikkers KL, et al. Effect of arginine deficiency on arginine-dependent post-translational protein modifications in miceBr J Nutr. (2005)
  13. a b Morris CR, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell diseaseJAMA. (2005)
  14. a b Diabetes-induced Coronary Vascular Dysfunction Involves Increased Arginase Activity.
  15. ^ Schramm L, et al. L-arginine deficiency and supplementation in experimental acute renal failure and in human kidney transplantationKidney Int. (2002)
  16. a b Adverse Gastrointestinal Effects of Arginine and Related Amino Acids.
  17. ^ Morris SM Jr. Recent advances in arginine metabolismCurr Opin Clin Nutr Metab Care. (2004)
  18. ^ De Bandt JP, et al. Metabolism of ornithine, alpha-ketoglutarate and arginine in isolated perfused rat liverBr J Nutr. (1995)
  19. ^ Curis E, et al. Almost all about citrulline in mammalsAmino Acids. (2005)
  20. ^ Plasma arginine and citrulline kinetics in adults given adequate and arginine-free diets.
  21. a b c Häberle J, et al. Suggested guidelines for the diagnosis and management of urea cycle disordersOrphanet J Rare Dis. (2012)
  22. ^ Bommarius AS, Makryaleas K, Drauz K. An enzymatic route to L-ornithine from L-arginine–activation and stabilization studies on L-arginaseBiomed Biochim Acta. (1991)
  23. ^ Bommarius AS, Drauz K. An enzymatic route to L-ornithine from arginine–activation, selectivity and stabilization of L-arginaseBioorg Med Chem. (1994)
  24. a b Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.
  25. ^ Dai Z, et al. Nitric oxide and energy metabolism in mammalsBiofactors. (2013)
  26. a b Molderings GJ, Haenisch B. Agmatine (decarboxylated L-arginine): physiological role and therapeutic potentialPharmacol Ther. (2012)
  27. ^ Regunathan S, Reis DJ. Characterization of arginine decarboxylase in rat brain and liver: distinction from ornithine decarboxylaseJ Neurochem. (2000)
  28. ^ Raasch W, et al. Agmatine, the bacterial amine, is widely distributed in mammalian tissuesLife Sci. (1995)
  29. ^ Raasch W, et al. Agmatine is widely and unequally distributed in rat organsAnn N Y Acad Sci. (1995)
  30. ^ Li G, et al. Agmatine: an endogenous clonidine-displacing substance in the brainScience. (1994)
  31. a b c d e f g Bode-Böger SM, et al. L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationshipBr J Clin Pharmacol. (1998)
  32. a b c d Tangphao O, et al. Pharmacokinetics of intravenous and oral L-arginine in normal volunteersBr J Clin Pharmacol. (1999)
  33. ^ White MF, Christensen HN. The two-way flux of cationic amino acids across the plasma membrane of mammalian cells is largely explained by a single transport systemJ Biol Chem. (1982)
  34. ^ White MF, Gazzola GC, Christensen HN. Cationic amino acid transport into cultured animal cells. I. Influx into cultured human fibroblastsJ Biol Chem. (1982)
  35. ^ MacLeod CL. Regulation of cationic amino acid transporter (CAT) gene expressionBiochem Soc Trans. (1996)
  36. ^ MacLeod CL, Finley KD, Kakuda DK. y(+)-type cationic amino acid transport: expression and regulation of the mCAT genesJ Exp Biol. (1994)
  37. ^ Identification and Characterization of a Membrane Protein (y+L Amino Acid Transporter-1) That Associates with 4F2hc to Encode the Amino Acid Transport Activity y+L A CANDIDATE GENE FOR LYSINURIC PROTEIN INTOLERANCE.
  38. ^ Verrey F, et al. New glycoprotein-associated amino acid transportersJ Membr Biol. (1999)
  39. a b c Dall’Asta V, et al. Arginine transport through system y(+)L in cultured human fibroblasts: normal phenotype of cells from LPI subjectsAm J Physiol Cell Physiol. (2000)
  40. a b c d e Collier SR, Casey DP, Kanaley JA. Growth hormone responses to varying doses of oral arginineGrowth Horm IGF Res. (2005)
  41. a b Jabecka A, et al. Oral L-arginine supplementation in patients with mild arterial hypertension and its effect on plasma level of asymmetric dimethylarginine, L-citruline, L-arginine and antioxidant statusEur Rev Med Pharmacol Sci. (2012)
  42. a b c d e Wilson AM, et al. L-arginine supplementation in peripheral arterial disease: no benefit and possible harmCirculation. (2007)
  43. a b Teerlink T. Letter by Teerlink regarding article, “L-arginine supplementation in peripheral arterial disease: no benefit and possible harm”Circulation. (2008)
  44. ^ Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampusNature. (1993)
  45. ^ Hawkins RD, Kandel ER, Siegelbaum SA. Learning to modulate transmitter release: themes and variations in synaptic plasticityAnnu Rev Neurosci. (1993)
  46. a b Huang EP. Synaptic plasticity: a role for nitric oxide in LTPCurr Biol. (1997)
  47. a b Schuman EM, Madison DV. A requirement for the intercellular messenger nitric oxide in long-term potentiationScience. (1991)
  48. ^ Arancio O, et al. Nitric oxide acts directly in the presynaptic neuron to produce long-term potentiation in cultured hippocampal neuronsCell. (1996)
  49. ^ Bartus K, Pigott B, Garthwaite J. Cellular targets of nitric oxide in the hippocampusPLoS One. (2013)
  50. a b O’Dell TJ, et al. Endothelial NOS and the blockade of LTP by NOS inhibitors in mice lacking neuronal NOSScience. (1994)
  51. ^ Endothelial nitric oxide synthase localized to hippocampal pyramidal cells: implications for synaptic plasticity.
  52. a b c Son H, et al. Long-term potentiation is reduced in mice that are doubly mutant in endothelial and neuronal nitric oxide synthaseCell. (1996)
  53. ^ Sakoda T, et al. Myristoylation of endothelial cell nitric oxide synthase is important for extracellular release of nitric oxideMol Cell Biochem. (1995)
  54. ^ Kantor DB, et al. A role for endothelial NO synthase in LTP revealed by adenovirus-mediated inhibition and rescueScience. (1996)
  55. ^ Lameu C, de Camargo AC, Faria M. L-arginine signalling potential in the brain: the peripheral gets centralRecent Pat CNS Drug Discov. (2009)
  56. ^ Flam BR, Eichler DC, Solomonson LP. Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycleNitric Oxide. (2007)
  57. ^ Xie L, Gross SS. Argininosuccinate synthetase overexpression in vascular smooth muscle cells potentiates immunostimulant-induced NO productionJ Biol Chem. (1997)
  58. ^ Husson A, et al. Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycleEur J Biochem. (2003)
  59. ^ Matarredona ER, et al. Nitric oxide synthesis inhibition increases proliferation of neural precursors isolated from the postnatal mouse subventricular zoneBrain Res. (2004)
  60. ^ Stoop R, Poo MM. Synaptic modulation by neurotrophic factorsProg Brain Res. (1996)
  61. ^ Lo DC. Neurotrophic factors and synaptic plasticityNeuron. (1995)
  62. ^ Hsieh HY, et al. Nitric oxide regulates BDNF release from nodose ganglion neurons in a pattern-dependent and cGMP-independent mannerJ Neurosci Res. (2010)
  63. ^ Lameu C, et al. Interactions between the NO-citrulline cycle and brain-derived neurotrophic factor in differentiation of neural stem cellsJ Biol Chem. (2012)
  64. ^ Kirschbaum C, Pirke KM, Hellhammer DH. The ‘Trier Social Stress Test’–a tool for investigating psychobiological stress responses in a laboratory settingNeuropsychobiology. (1993)
  65. a b Jezova D, et al. Subchronic treatment with amino acid mixture of L-lysine and L-arginine modifies neuroendocrine activation during psychosocial stress in subjects with high trait anxietyNutr Neurosci. (2005)
  66. ^ Jezova D, et al. High trait anxiety in healthy subjects is associated with low neuroendocrine activity during psychosocial stressProg Neuropsychopharmacol Biol Psychiatry. (2004)
  67. ^ Smriga M, et al. Oral treatment with L-lysine and L-arginine reduces anxiety and basal cortisol levels in healthy humansBiomed Res. (2007)
  68. ^ Dietary L-Lysine Deficiency Increases Stress-Induced Anxiety and Fecal Excretion in Rats.
  69. ^ Lysine fortification reduces anxiety and lessens stress in family members in economically weak communities in northwest Syria.
  70. ^ Chang YF, Gao XM. L-lysine is a barbiturate-like anticonvulsant and modulator of the benzodiazepine receptorNeurochem Res. (1995)
  71. ^ Hasler WL. Lysine as a serotonin receptor antagonist: using the diet to modulate gut functionGastroenterology. (2004)
  72. ^ Smriga M, Torii K. L-Lysine acts like a partial serotonin receptor 4 antagonist and inhibits serotonin-mediated intestinal pathologies and anxiety in ratsProc Natl Acad Sci U S A. (2003)
  73. ^ Smriga M, Torii K. Prolonged treatment with L-lysine and L-arginine reduces stress-induced anxiety in an elevated plus mazeNutr Neurosci. (2003)
  74. ^ Joung HY, et al. The differential role of NOS inhibitors on stress-induced anxiety and neuroendocrine alterations in the ratBehav Brain Res. (2012)
  75. ^ Malinski T. Nitric oxide and nitroxidative stress in Alzheimer’s diseaseJ Alzheimers Dis. (2007)
  76. ^ McCann SM, et al. The nitric oxide theory of aging revisitedAnn N Y Acad Sci. (2005)
  77. a b Calabrese V, et al. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicityNat Rev Neurosci. (2007)
  78. ^ Rushaidhi M, et al. Aging affects L-arginine and its metabolites in memory-associated brain structures at the tissue and synaptoneurosome levelsNeuroscience. (2012)
  79. ^ Liu P, Jing Y, Zhang H. Age-related changes in arginine and its metabolites in memory-associated brain structuresNeuroscience. (2009)
  80. ^ Neural plasticity in the ageing brain.
  81. ^ Greenwood PM. Functional plasticity in cognitive aging: review and hypothesisNeuropsychology. (2007)
  82. a b Stuehr DJ. Structure-function aspects in the nitric oxide synthasesAnnu Rev Pharmacol Toxicol. (1997)
  83. ^ Charles IG, et al. Expression of human nitric oxide synthase isozymesMethods Enzymol. (1996)
  84. ^ Casas JP, et al. Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE reviewAm J Epidemiol. (2006)
  85. ^ Griffith OW, Stuehr DJ. Nitric oxide synthases: properties and catalytic mechanismAnnu Rev Physiol. (1995)
  86. ^ Marletta MA. Nitric oxide synthase structure and mechanismJ Biol Chem. (1993)
  87. ^ Masters BS. Nitric oxide synthases: why so complexAnnu Rev Nutr. (1994)
  88. ^ Mayer B, et al. Brain nitric oxide synthase is a biopterin- and flavin-containing multi-functional oxido-reductaseFEBS Lett. (1991)
  89. ^ Hevel JM, White KA, Marletta MA. Purification of the inducible murine macrophage nitric oxide synthase. Identification as a flavoproteinJ Biol Chem. (1991)
  90. ^ Stuehr DJ, et al. Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: an FAD- and FMN-containing flavoproteinProc Natl Acad Sci U S A. (1991)
  91. ^ Mayer B, Hemmens B. Biosynthesis and action of nitric oxide in mammalian cellsTrends Biochem Sci. (1997)
  92. ^ Ghosh DK, Abu-Soud HM, Stuehr DJ. Reconstitution of the second step in NO synthesis using the isolated oxygenase and reductase domains of macrophage NO synthaseBiochemistry. (1995)
  93. ^ Lekakis JP, et al. Oral L-arginine improves endothelial dysfunction in patients with essential hypertensionInt J Cardiol. (2002)
  94. ^ L-Arginine and Atherothrombosis.
  95. a b Lucotti P, et al. Beneficial effects of a long-term oral L-arginine treatment added to a hypocaloric diet and exercise training program in obese, insulin-resistant type 2 diabetic patientsAm J Physiol Endocrinol Metab. (2006)
  96. a b c d e f Acute L-arginine supplementation reduces the O2 cost of moderate-intensity exercise and enhances high-intensity exercise tolerance.
  97. a b Fahs CA, Heffernan KS, Fernhall B. Hemodynamic and vascular response to resistance exercise with L-arginineMed Sci Sports Exerc. (2009)
  98. a b c Tang JE, et al. Bolus arginine supplementation affects neither muscle blood flow nor muscle protein synthesis in young men at rest or after resistance exerciseJ Nutr. (2011)
  99. a b c Alvares TS, et al. Acute l-arginine supplementation increases muscle blood volume but not strength performanceAppl Physiol Nutr Metab. (2012)
  100. ^ Durante W, Johnson FK, Johnson RA. Arginase: a critical regulator of nitric oxide synthesis and vascular functionClin Exp Pharmacol Physiol. (2007)
  101. ^ Baydoun AR, et al. Substrate-dependent regulation of intracellular amino acid concentrations in cultured bovine aortic endothelial cellsBiochem Biophys Res Commun. (1990)
  102. ^ Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginineNature. (1988)
  103. ^ Cardounel AJ, et al. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular functionJ Biol Chem. (2007)
  104. a b Hardy TA, May JM. Coordinate regulation of L-arginine uptake and nitric oxide synthase activity in cultured endothelial cellsFree Radic Biol Med. (2002)
  105. a b Bode-Böger SM, Scalera F, Ignarro LJ. The L-arginine paradox: Importance of the L-arginine/asymmetrical dimethylarginine ratioPharmacol Ther. (2007)
  106. a b Shin S, Mohan S, Fung HL. Intracellular L-arginine concentration does not determine NO production in endothelial cells: implications on the “L-arginine paradox”Biochem Biophys Res Commun. (2011)
  107. a b c Liu TH, et al. No effect of short-term arginine supplementation on nitric oxide production, metabolism and performance in intermittent exercise in athletesJ Nutr Biochem. (2009)
  108. ^ Tsukahara H, Gordienko DV, Goligorsky MS. Continuous monitoring of nitric oxide release from human umbilical vein endothelial cellsBiochem Biophys Res Commun. (1993)
  109. a b Joshi MS, et al. Receptor-mediated activation of nitric oxide synthesis by arginine in endothelial cellsProc Natl Acad Sci U S A. (2007)
  110. a b McDonald KK, et al. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the “arginine paradox”J Biol Chem. (1997)
  111. ^ Zani BG, Bohlen HG. Transport of extracellular l-arginine via cationic amino acid transporter is required during in vivo endothelial nitric oxide productionAm J Physiol Heart Circ Physiol. (2005)
  112. ^ Kone BC. Protein-protein interactions controlling nitric oxide synthasesActa Physiol Scand. (2000)
  113. a b Vallance P, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failureLancet. (1992)
  114. a b Böger RH, et al. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive diseaseJ Am Coll Cardiol. (1998)
  115. a b Mittermayer F, et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery diseaseArterioscler Thromb Vasc Biol. (2006)
  116. ^ ADMA, Endothelial Progenitor Cells, and Cardiovascular Risk.
  117. ^ Effects of asymmetric dimethylarginine (ADMA) infusion in humans.
  118. ^ Kielstein JT, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humansCirculation. (2004)
  119. a b Cooke JP. Asymmetrical dimethylarginine: the Uber markerCirculation. (2004)
  120. ^ Leiper JM, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminasesBiochem J. (1999)
  121. ^ Jacobi J, et al. Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesisCirculation. (2005)
  122. ^ Stühlinger MC, et al. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginineCirculation. (2001)
  123. ^ Drexler H, et al. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginineLancet. (1991)
  124. ^ Ito A, et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolaseCirculation. (1999)
  125. ^ Lin KY, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolaseCirculation. (2002)
  126. ^ Willoughby DS, et al. Effects of 7 days of arginine-alpha-ketoglutarate supplementation on blood flow, plasma L-arginine, nitric oxide metabolites, and asymmetric dimethyl arginine after resistance exerciseInt J Sport Nutr Exerc Metab. (2011)
  127. a b c d Schwedhelm E, et al. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolismBr J Clin Pharmacol. (2008)
  128. ^ Ochiai M, et al. Short-term effects of L-citrulline supplementation on arterial stiffness in middle-aged menInt J Cardiol. (2012)
  129. ^ Bode-Böger SM, et al. L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled studyCirculation. (1996)
  130. ^ Sydow K, et al. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-toleranceJ Clin Invest. (2004)
  131. ^ Witte DR, et al. Measurement of flow-mediated dilatation of the brachial artery is affected by local elastic vessel wall properties in high-risk patientsAtherosclerosis. (2005)
  132. ^ Lind L. Arterial compliance influences the measurement of flow-mediated vasodilation, but not acetylcholine-mediated forearm blood flow. The Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) studyAtherosclerosis. (2007)
  133. a b Vasilijevic A, et al. Beneficial effects of L-arginine nitric oxide-producing pathway in rats treated with alloxanJ Physiol. (2007)
  134. ^ Méndez JD, Hernández Rde H. L-arginine and polyamine administration protect beta-cells against alloxan diabetogenic effect in Sprague-Dawley ratsBiomed Pharmacother. (2005)
  135. a b Mohan IK, Das UN. Effect of L-arginine-nitric oxide system on chemical-induced diabetes mellitusFree Radic Biol Med. (1998)
  136. ^ Lindsay RM, et al. N omega-nitro-L-arginine methyl ester reduces the incidence of IDDM in BB/E ratsDiabetes. (1995)
  137. ^ Kaneto H, et al. Apoptotic cell death triggered by nitric oxide in pancreatic beta-cellsDiabetes. (1995)
  138. ^ DiMagno MJ, et al. Secretagogue-stimulated pancreatic secretion is differentially regulated by constitutive NOS isoforms in miceAm J Physiol Gastrointest Liver Physiol. (2004)
  139. a b c Monti LD, et al. Effect of a long-term oral l-arginine supplementation on glucose metabolism: a randomized, double-blind, placebo-controlled trialDiabetes Obes Metab. (2012)
  140. ^ Tang WH, et al. Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular riskJ Am Coll Cardiol. (2009)
  141. ^ Sourij H, et al. Arginine bioavailability ratios are associated with cardiovascular mortality in patients referred to coronary angiographyAtherosclerosis. (2011)
  142. ^ Jabłecka A, et al. The effect of oral L-arginine supplementation on fasting glucose, HbA1c, nitric oxide and total antioxidant status in diabetic patients with atherosclerotic peripheral arterial disease of lower extremitiesEur Rev Med Pharmacol Sci. (2012)
  143. a b Álvares TS, et al. L-Arginine as a potential ergogenic aid in healthy subjectsSports Med. (2011)
  144. ^ Long JH, et al. Arginine supplementation induces myoblast fusion via augmentation of nitric oxide productionJ Muscle Res Cell Motil. (2006)
  145. ^ Maxwell AJ, et al. L-arginine enhances aerobic exercise capacity in association with augmented nitric oxide productionJ Appl Physiol. (2001)
  146. ^ Schaefer A, et al. L-arginine reduces exercise-induced increase in plasma lactate and ammoniaInt J Sports Med. (2002)
  147. ^ Wax B, et al. Acute L-arginine alpha ketoglutarate supplementation fails to improve muscular performance in resistance trained and untrained menJ Int Soc Sports Nutr. (2012)
  148. ^ Abel T, et al. Influence of chronic supplementation of arginine aspartate in endurance athletes on performance and substrate metabolism – a randomized, double-blind, placebo-controlled studyInt J Sports Med. (2005)
  149. ^ Colombani PC, et al. Chronic arginine aspartate supplementation in runners reduces total plasma amino acid level at rest and during a marathon runEur J Nutr. (1999)
  150. ^ McConell GK. Effects of L-arginine supplementation on exercise metabolismCurr Opin Clin Nutr Metab Care. (2007)
  151. ^ McKnight JR, et al. Beneficial effects of L-arginine on reducing obesity: potential mechanisms and important implications for human healthAmino Acids. (2010)
  152. a b c d e Zajac A, et al. Arginine and ornithine supplementation increases growth hormone and insulin-like growth factor-1 serum levels after heavy-resistance exercise in strength-trained athletesJ Strength Cond Res. (2010)
  153. a b c d Kanaley JA. Growth hormone, arginine and exerciseCurr Opin Clin Nutr Metab Care. (2008)
  154. ^ Oral arginine attenuates the growth hormone response to resistance exercise.
  155. a b Marcell TJ, et al. Oral arginine does not stimulate basal or augment exercise-induced GH secretion in either young or old adultsJ Gerontol A Biol Sci Med Sci. (1999)
  156. a b Borst SE, Millard WJ, Lowenthal DT. Growth hormone, exercise, and aging: the future of therapy for the frail elderlyJ Am Geriatr Soc. (1994)
  157. a b Fogelholm GM, et al. Low-dose amino acid supplementation: no effects on serum human growth hormone and insulin in male weightliftersInt J Sport Nutr. (1993)
  158. ^ Veldhuis JD, Bowers CY. Regulated recovery of pulsatile growth hormone secretion from negative feedback: a preclinical investigationAm J Physiol Regul Integr Comp Physiol. (2011)
  159. ^ Veldhuis JD, et al. Neurophysiological regulation and target-tissue impact of the pulsatile mode of growth hormone secretion in the humanGrowth Horm IGF Res. (2001)
  160. ^ Besset A, et al. Increase in sleep related GH and Prl secretion after chronic arginine aspartate administration in manActa Endocrinol (Copenh). (1982)
  161. ^ Barbul A, et al. Arginine enhances wound healing and lymphocyte immune responses in humansSurgery. (1990)
  162. ^ Shi HP, et al. Supplemental L-arginine enhances wound healing in diabetic ratsWound Repair Regen. (2003)
  163. ^ Debats IB, et al. Role of arginine in superficial wound healing in manNitric Oxide. (2009)
  164. ^ Shi HP, et al. Supplemental dietary arginine enhances wound healing in normal but not inducible nitric oxide synthase knockout miceSurgery. (2000)
  165. ^ Shi HP, et al. Effect of supplemental ornithine on wound healingJ Surg Res. (2002)
  166. ^ Campbell B, et al. Pharmacokinetics, safety, and effects on exercise performance of L-arginine alpha-ketoglutarate in trained adult menNutrition. (2006)
  167. ^ Cynober L, et al. Action of ornithine alpha-ketoglutarate, ornithine hydrochloride, and calcium alpha-ketoglutarate on plasma amino acid and hormonal patterns in healthy subjectsJ Am Coll Nutr. (1990)
  168. a b c Moinard C, et al. Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic studyBr J Nutr. (2008)
  169. ^ Rougé C, et al. Manipulation of citrulline availability in humansAm J Physiol Gastrointest Liver Physiol. (2007)
  170. ^ Thibault R, et al. Oral citrulline does not affect whole body protein metabolism in healthy human volunteers: results of a prospective, randomized, double-blind, cross-over studyClin Nutr. (2011)
  171. ^ Sureda A, et al. L-citrulline-malate influence over branched chain amino acid utilization during exerciseEur J Appl Physiol. (2010)
  172. ^ Isidori A, Lo Monaco A, Cappa M. A study of growth hormone release in man after oral administration of amino acidsCurr Med Res Opin. (1981)
  173. ^ Shao A, Hathcock JN. Risk assessment for the amino acids taurine, L-glutamine and L-arginineRegul Toxicol Pharmacol. (2008)
  174. ^ Hellier MD, Holdsworth CD, Perrett D. Dibasic amino acid absorption in manGastroenterology. (1973)
  175. ^ Izzo AA, Mascolo N, Capasso F. Nitric oxide as a modulator of intestinal water and electrolyte transportDig Dis Sci. (1998)